Earth-mass dark-matter haloes as the first structures in the early Universe

The Universe was nearly smooth and homogeneous before a redshift of z = 100, about 20 million years after the Big Bang. After this epoch, the tiny fluctuations imprinted upon the matter distribution during the initial expansion began to collapse because of gravity. The properties of these fluctuations depend on the unknown nature of dark matter, the determination of which is one of the biggest challenges in present-day science. Here we report supercomputer simulations of the concordance cosmological model, which assumes neutralino dark matter (at present the preferred candidate), and find that the first objects to form are numerous Earth-mass dark-matter haloes about as large as the Solar System. They are stable against gravitational disruption, even within the central regions of the Milky Way. We expect over 10(15) to survive within the Galactic halo, with one passing through the Solar System every few thousand years. The nearest structures should be among the brightest sources of gamma-rays (from particle-particle annihilation).

Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model

In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model.

Gi alpha 1 selectively couples somatostatin receptor subtype 3 to adenylyl cyclase: identification of the functional domains of this alpha subunit necessary for mediating the inhibition by somatostatin of cAMP formation

A major cellular action of the neuropeptide somatostatin (SRIF) is the inhibition of adenylyl cyclase activity. SRIF induces this effect after its interaction with membrane-bound receptors. Five SRIF receptors (SSTRs), which differ in their functional coupling to adenylyl cyclase, have recently been cloned. The third SSTR cloned, SSTR3, effectively mediates the inhibition of adenylyl cyclase by SRIF. The molecular mechanism by which SRIF modulates intracellular cAMP synthesis via SSTR3 was investigated by initially identifying which G alpha subunits are involved in coupling SSTR3 to adenylyl cyclase. SRIF did not inhibit cAMP formation in Chinese hamster ovary cells stably expressing SSTR3 and Gi alpha 2 or Gi alpha 3 but lacking Gi alpha 1. However, SRIF did inhibit forskolin-stimulated cAMP formation in Chinese hamster ovary cells stably expressing SSTR3 and Gi alpha 1, indicating that Gi alpha 1 selectively couples SSTR3 to adenylyl cyclase. To investigate the functional domains of Gi alpha 1 necessary for interaction with SSTR3, a chimeric alpha subunit (Gi alpha 2/Gi alpha 1) was constructed, consisting of the amino-terminal two thirds of Gi alpha 2 ligated to the carboxyl-terminal third of Gi alpha 1. SRIF inhibited cAMP formation in cells expressing SSTR3 and the Gi alpha 2/Gi alpha 1 chimera. These findings indicate that the carboxy-terminal third of Gi alpha 1 interacts with SSTR3 and is important in transmitting the signal of SSTR3 activation to adenylyl cyclase. In contrast, a similar Gi alpha 2/Gi alpha 3 chimera did not couple SSTR3 to adenylyl cyclase, further indicating that Gi alpha 3 does not contribute to SRIF inhibition of adenylyl cyclase activity. These findings demonstrate that Gi alpha 1 selectively couples SSTR3 to adenylyl cyclase, and they indicate that the carboxyl-terminal region of this alpha subunit is involved in mediating SRIF inhibition of adenylyl cyclase activity.

Evidence for the involvement of carbohydrate moieties in the adhesion of U937 cells to tumor necrosis factor-alpha (TNFalpha)-stimulated vascular endothelium in vitro

Treatment of U937 cells with fructose 1-phosphate (P) and fucoidan dose-dependently inhibited the adhesion of these monocytic cells to TNF alpha-stimulated human umbilical vein endothelial cells (HUVEC) (IC50 = 1 mM and 10 micrograms/ml respectively). These carbohydrates (CHO) failed to inhibit U937 adhesion to unstimulated (basal) HUVEC or phorbol 12, 13 dibutyrate (PdBu)-stimulated HUVEC. At 10 mM concentration, both fucose 1-P and lactose 1-P inhibited TNF alpha-stimulated adhesion while the latter also inhibited basal adhesion. Fructose 6-P, fucose, galactose 1-P, glucose 1-P, glucose 6-P, glucuronic acid, beta-glycerol 1-P, mannose 1-P, mannose 6-P, ribose 1-P and ribose 5-P tested at 10 mM did not inhibit U937 cells adhesion to basal or TNF alpha-stimulated HUVEC. These data suggest that CHO may play an important role in modulating monocytes adhesion to cytokine-induced adhesion molecule(s) on the surface of HUVEC.

Leukotriene C4 ([3H]-LTC4) binding to membranes isolated from a hamster smooth muscle cell line (DDT1MF2)

Leukotriene C4 (LTC4) has been demonstrated to induce contraction of the smooth muscle cell line DDT1MF2. A partially purified membrane fraction obtained from these cells exhibited a high affinity binding site for LTC4. Binding of [3H]-LTC4 was saturable, specific and reversible with a dissociation constant (Kd) of 21 +/- 4 nM. The maximum number of binding sites (Bmax) was 55 +/- 5 pmol/mg of protein. Specificity was demonstrated in competition studies in which the Ki of LTC4 against specifically bound [3H]-LTC4 was 12 nM whereas Leukotriene D4 (LTD4) and Leukotriene E4 (LTE4) had a Ki of 38 +/- 4 and 4.7 +/- 0.5 nM respectively. A previously described antagonist of leukotriene-induced smooth muscle contraction PFL 55712 had a Ki of 23 +/- 2 nM as determined by competition binding experiments.